In FGFR1-amplified lung cancer cell lines, MET-amplification is a mechanism of resistance to FGFR-targeting drugs71–74 and conversely, FGFR1-dependent resistance to MET inhibitors is observed in leukaemia, kidney and prostate cancers75–77. Here, FGFR1 is linked to prostatitis.